GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Cash From Other Investing Activities

NYMXF (Nymox Pharmaceutical) Cash From Other Investing Activities : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Cash From Other Investing Activities?

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Nymox Pharmaceutical's cash from other investing activities for the three months ended in Dec. 2024 was $0.00 Mil. It means Nymox Pharmaceutical received $0.00 Mil from other investing activities. Nymox Pharmaceutical's cash from other investing activities for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.


Nymox Pharmaceutical Cash From Other Investing Activities Historical Data

The historical data trend for Nymox Pharmaceutical's Cash From Other Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Cash From Other Investing Activities Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash From Other Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
Cash From Other Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nymox Pharmaceutical Cash From Other Investing Activities Calculation

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cash From Other Investing Activities for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical Cash From Other Investing Activities Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Cash From Other Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical Business Description

Industry
Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical Headlines

From GuruFocus

Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review

By GlobeNewswire GlobeNewswire 02-15-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 07-02-2022

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022

Nymox Announces Closing of $6.4 Million Financing

By GuruFocusNews GuruFocusNews 04-04-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022

Nymox Announces $2 Million Private Placement

By Marketwired 08-02-2023

NYMOX Announces New Marketing Submission for NYMOZARFEX� for BPH

By Value_Insider Value_Insider 12-05-2022